ContraFect Corporation Announces Separation of Units Sold in IPO

YONKERS, NY — (Marketwired) — 09/09/14 — ContraFect Corporation (NASDAQ: CFRXU), a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, announced today that the units issued in ContraFect’s recent initial public offering will separate on September 12, 2014. Each unit consists of one share of our common stock, one Class A warrant to purchase one share of our common stock and one Class B warrant to purchase one-half share of our common stock.

This entry was posted in Recent Development News: Q3 – 2014. Bookmark the permalink.